These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
543 related articles for article (PubMed ID: 25279542)
1. CpG oligodeoxynucleotide inhibits HBV replication in a hydrodynamic injection murine model. Hu W; Huang H; Zhang TY; Mao YY; Wang XJ; Wang SQ Antivir Ther; 2015; 20(3):289-95. PubMed ID: 25279542 [TBL] [Abstract][Full Text] [Related]
2. High persistence rate of hepatitis B virus in a hydrodynamic injection-based transfection model in C3H/HeN mice. Peng XH; Ren XN; Chen LX; Shi BS; Xu CH; Fang Z; Liu X; Chen JL; Zhang XN; Hu YW; Zhou XH World J Gastroenterol; 2015 Mar; 21(12):3527-36. PubMed ID: 25834317 [TBL] [Abstract][Full Text] [Related]
3. Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro. Vincent IE; Lucifora J; Durantel D; Hantz O; Chemin I; Zoulim F; Trepo C Antivir Ther; 2009; 14(1):131-5. PubMed ID: 19320247 [TBL] [Abstract][Full Text] [Related]
4. Susceptibility of different hepatitis B virus isolates to interferon-alpha in a mouse model based on hydrodynamic injection. Song J; Zhou Y; Li S; Wang B; Zheng X; Wu J; Gibbert K; Dittmer U; Lu M; Yang D PLoS One; 2014; 9(3):e90977. PubMed ID: 24618716 [TBL] [Abstract][Full Text] [Related]
5. Different antiviral effects of IFNα and IFNβ in an HBV mouse model. Zhou Y; Li S; Tang Z; Xu C; Huang S; Wu J; Dittmer U; Dickow J; Sutter K; Lu M; Yang D; Song J Immunobiology; 2017 Mar; 222(3):562-570. PubMed ID: 27839836 [TBL] [Abstract][Full Text] [Related]
6. Establishment and primary application of a mouse model with hepatitis B virus replication. Liu FJ; Liu L; He F; Wang S; Zhou TY; Liu C; Deng LY; Tang H World J Gastroenterol; 2007 Oct; 13(40):5324-30. PubMed ID: 17879401 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of the hepatitis B virus replication in vitro by an oligodeoxynucleotide containing cytidine-guanosine motifs. Li N; Fan XG; Chen ZH; Zhu C; Liu HB; Huang Y Immunol Lett; 2006 Jan; 102(1):60-6. PubMed ID: 16105691 [TBL] [Abstract][Full Text] [Related]
8. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B. Manesis EK; Papatheodoridis GV; Tiniakos DG; Hadziyannis ES; Agelopoulou OP; Syminelaki T; Papaioannou C; Nastos T; Karayiannis P J Hepatol; 2011 Jul; 55(1):61-8. PubMed ID: 21145875 [TBL] [Abstract][Full Text] [Related]
9. [Effects of amantadine and biphenyl dimethyl dicarboxylate on hepatitis B virus in hepatitis B virus replication mice]. Liu F; Jiang Z; Zhou Q; Yu Y; Meng H; Shi Y Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2014 Apr; 31(2):400-4. PubMed ID: 25039150 [TBL] [Abstract][Full Text] [Related]
10. [Study on inhibitory effect of CpG-ODN on HBV replication in vitro]. Li N; Fan XG; Chen ZH; Zhu C Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Jan; 21(1):103-5. PubMed ID: 15629096 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of NVR 3-778, Alone and In Combination With Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection. Klumpp K; Shimada T; Allweiss L; Volz T; Lütgehetmann M; Hartman G; Flores OA; Lam AM; Dandri M Gastroenterology; 2018 Feb; 154(3):652-662.e8. PubMed ID: 29079518 [TBL] [Abstract][Full Text] [Related]
12. Predictive value of interferon-gamma inducible protein 10 kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients. Wang Y; Zhao C; Zhang L; Yu W; Shen C; Wang W; Zhen Z; Zhou J Antiviral Res; 2014 Mar; 103():51-9. PubMed ID: 24418572 [TBL] [Abstract][Full Text] [Related]
13. Anti-hepatitis B virus activities of α-DDB-FNC, a novel nucleoside-biphenyldicarboxylate compound in cells and ducks, and its anti-immunological liver injury effect in mice. Yang Q; Zhao X; Zang L; Fang X; Zhao J; Yang X; Wang Q; Zheng L; Chang J Antiviral Res; 2012 Dec; 96(3):333-9. PubMed ID: 23098744 [TBL] [Abstract][Full Text] [Related]
14. Anti-HBV effects of CpG oligodeoxynucleotide-activated peripheral blood mononuclear cells from patients with chronic hepatitis B. Li N; Fan XG; Chen ZH; Huang Y; Quan J; Liu ZB APMIS; 2005 Oct; 113(10):647-54. PubMed ID: 16309422 [TBL] [Abstract][Full Text] [Related]
15. The doses of plasmid backbone plays a major role in determining the HBV clearance in hydrodynamic injection mouse model. Wang X; Zhu J; Zhang Y; Li Y; Ma T; Li Q; Xu J; Xu L Virol J; 2018 May; 15(1):89. PubMed ID: 29783985 [TBL] [Abstract][Full Text] [Related]
16. Combination therapy including CpG oligodeoxynucleotides and entecavir induces early viral response and enhanced inhibition of viral replication in a woodchuck model of chronic hepadnaviral infection. Meng Z; Zhang X; Pei R; Zhang E; Kemper T; Vollmer J; Davis HL; Glebe D; Gerlich W; Roggendorf M; Lu M Antiviral Res; 2016 Jan; 125():14-24. PubMed ID: 26585244 [TBL] [Abstract][Full Text] [Related]
17. Nanoparticles encapsulating hepatitis B virus cytosine-phosphate-guanosine induce therapeutic immunity against HBV infection. Lv S; Wang J; Dou S; Yang X; Ni X; Sun R; Tian Z; Wei H Hepatology; 2014 Feb; 59(2):385-94. PubMed ID: 23907803 [TBL] [Abstract][Full Text] [Related]
18. Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection. Marinos G; Naoumov NV; Williams R Hepatology; 1996 Nov; 24(5):991-5. PubMed ID: 8903365 [TBL] [Abstract][Full Text] [Related]
19. [Quantitative detection of intrahepatic hepatitis B virus DNA in patients with chronic hepatitis B]. Lu H; Ma LX; Xu WS; Zhang HY; Yu LJ; Duan HY Zhonghua Gan Zang Bing Za Zhi; 2003 Mar; 11(3):173-5. PubMed ID: 12681068 [TBL] [Abstract][Full Text] [Related]
20. Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B. Chen Y; Li X; Ye B; Yang X; Wu W; Chen B; Pan X; Cao H; Li L Antiviral Res; 2011 Jul; 91(1):23-31. PubMed ID: 21549152 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]